Search Results - "Machui, Paul"

Enantioselective Biocatalytic Reduction of 2H‑1,4-Benzoxazines Using Imine Reductases by Zumbrägel, Nadine, Machui, Paul, Nonnhoff, Jannis, Gröger, Harald

“…A biocatalytic reduction of 2H-1,4-benzoxazines using imine reductases is reported. This process enables a smooth and enantioselective synthesis of the…”
Get full text

Enantioselective Biocatalytic Reduction of 2 H-1,4-Benzoxazines Using Imine Reductases by Zumbrägel, Nadine, Machui, Paul, Nonnhoff, Jannis, Gröger, Harald

“…A biocatalytic reduction of 2 H-1,4-benzoxazines using imine reductases is reported. This process enables a smooth and enantioselective synthesis of the…”
Get full text

Compact hydrophilic electrophiles enable highly efficacious high DAR ADCs with excellent PK profile by Ochtrop, Philipp, Jahzerah, Jahaziel, Machui, Paul, Mai, Isabelle, Schumacher, Dominik, Helma, Jonas, Kasper, Marc-André, Hackenberger, Christian P. R

“…The recent success of antibody-drug conjugates (ADC), exemplified by seven new FDA-approvals within three years, has led to increased attention for antibody…”
Get full text

Compact hydrophilic electrophiles enable highly efficacious high DAR ADCs with excellent in vivo PK profile by Ochtrop, Philipp, Jahzerah, Jahaziel, Machui, Paul, Mai, Isabelle, Schumacher, Dominik, Helma, Jonas, Kasper, Marc-André, Hackenberger, Christian P R

“…The recent success of antibody-drug conjugates (ADC), exemplified by seven new FDA-approvals within three years, has led to increased attention for antibody…”
Get full text

Design and Evaluation of Phosphonamidate-Linked Exatecan Constructs for Highly Loaded, Stable, and Efficacious Antibody-Drug Conjugates by Schmitt, Saskia, Machui, Paul, Mai, Isabelle, Herterich, Sarah, Wunder, Swetlana, Cyprys, Philipp, Gerlach, Marcus, Ochtrop, Philipp, Hackenberger, Christian P R, Schumacher, Dominik, Helma, Jonas, Vogl, Annette M, Kasper, Marc-André

“…Topoisomerase I (TOP1) Inhibitors constitute an emerging payload class to engineer antibody-drug conjugates (ADC) as next-generation biopharmaceutical for…”
Get more information

Abstract 2623: Enabling 5T4 for targeted cancer therapy: TUB-030, a novel ADC built with ethynylphosphonamidate conjugation chemistry, shows long-lasting anti-tumor activity via Topoisomerase-I inhibition with an optimized therapeutic index by Schmitt, Saskia, Mai, Isabelle, Machui, Paul, Herterich, Sarah, Hauswald, Danila, Ochtrop, Philipp, Cyprys, Philipp, Kozlowska, Izabela, Kitowski, Annabel, Gerlach, Marcus, Marcq, Olivier, Trail, Pamela A., Schumacher, Dominik, Kasper, Marc-André, Fingerle-Rowson, Günter, Hock, Björn, Helma-Smets, Jonas, Vogl, Annette M.

“…Abstract TUB-030 is a novel Antibody-Drug Conjugate (ADC) targeting the oncofetal 5T4 antigen, a glycoprotein, that is functionally involved in regulation of…”
Get full text

Abstract 2622: TUB-040, a novel Napi2b-targeting ADC built with ethynylphosphonamidate conjugation chemistry, demonstrates high and long-lasting anti-tumor efficacy via Topoisomerase-I inhibition and excellent tolerability predictive of a wide therapeutic window in humans by Schmitt, Saskia, Mai, Isabelle, Machui, Paul, Herterich, Sarah, Hauswald, Danila, Ochtrop, Philipp, Cyprys, Philipp, Kozlowska, Izabela, Kitowski, Annabel, Gerlach, Marcus, Marcq, Olivier, Trail, Pamela A., Schumacher, Dominik, Kasper, Marc-André, Fingerle-Rowson, Günter, Hock, Björn, Helma-Smets, Jonas, Vogl, Annette M.

“…Abstract TUB-040 is a novel Antibody-Drug Conjugate (ADC) targeting Napi2b, a highly overexpressed target in ovarian cancer and lung adenocarcinoma. Napi2b is…”
Get full text